Advances in Metabolomics Research

Research in metabolomics is paving the way for advances in many fields such as plant engineering, crop protection, development of new pesticides, aquaculture—the environment as a whole. At present, metabolomics aid decision making in the discovery of biomarkers. Saliva, urine, bile, and seminal fluids can be analyzed for discovering new biomarkers. The potential of metabolomics in discovering hundreds of metabolites is expected to play a major role in medical diagnostics, personalized medicine, and personalized treatment.

Research in Orthopedics

Initially, metabolomic study was conducted for osteoarthritis. Studies of metabolite profiles of samples of synovial fluid, serum, synovial tissue, and urine revealed many differential metabolites and metabolic pathways. Metabolic studies of bone tumors, osteoporosis, and spondylitis have established potential biomarkers that help to further understand the pathogenesis of the consequent diseases. Earlier study results of orthopedic diseases are found to be satisfactory, which may pave the way for further research in the field of orthopedics.

Research in neurological disease

At present the clinical criteria for neurological diseases, such as Parkinson’s and Alzheimer’s, are not considered satisfactory. Metabolomics can help to discover novel biomarkers, biochemical pathways for improving disease diagnosis, and thus determine the treatment. The recent advancements in identifying many novel biomarkers for neurological disorders is greatly enhanced due to extensive research in the field of metabolomics. These biomarkers are more precise than the usual clinical practice. Cerebrospinal fluid (CSF) could be a rich biomarker source and used for the diagnosis of neurological diseases. It is expected that metabolomics will facilitate the analysis of CSF and help in improving the development of beneficial treatments for humans.

Analyzing the urine samples of kidney cancer patients and healthy individuals revealed differential accumulation of gentisate, quinolinate, acylcarnitines, and 4-hydroxybenzoate. To differentiate further between kidney cancer patients and normal population, metabolic analysis of tissue and serum samples are used.

Metabolic analysis of serum and urine samples helps in early diagnosis of breast cancer and ovarian cancer. Analyzing biopsy samples of breast tissue serves as a secondary form of confirmation for breast cancer. Analyzing samples of ovarian cancer patients has shown metabolic differentiation between borderline tumors and ovarian carcinomas.

Developing diagnostic biomarkers for detecting colorectal cancer (CRC) is being explored through metabolomics. Metabolic analysis of serum samples has revealed four metabolites — cystamine, aspartic acid, 2-hydroxybutyrate, and kynurenine, which serve as a basis in early diagnosis of CRC. In CRC, based on adjacent tumor stages, metabolite profiling distinguishes among mucosa samples and between samples of adjacent mucosa and tumor. Significant variation in mucosae levels between normal and tissue sample of CRC has been identified in over 30 marker metabolites, most of which are from pathways such as lipid metabolism, glycolysis, and nucleotide biosynthesis, all of which are probably disturbed in cancer.

Metabolomic studies are focused on bone metastases and leptomeningeal carcinomatosis. Comparing samples from cancerous and normal bone metastases has shown that cholesterol levels are higher in prostate cancer bone metastates.

Metabolomics helps in distinguishing the various cancer stages. The serum analysis of patients with pancreatic cancer can differentiate between stage III and stage IV groups (both IVa and IVb groups).

Advances in Pharmacometabolomics

Another emerging research area is pharmacometabolomics, where metabolomics are used to observe the physiological responses of the toxicity of drugs. Studies on CRC patients to find the drug efficacy of capecitabine found that the lipoprotein-derived cholesterol levels correlate with the toxicity intensity, leading to predictive competencies. Current studies are limited to oncology; however, more and more future research is expected to focus on the field of pharmacometabolomics.

2016 Nobel Laureate in Chemistry Fraser Stoddart outlines his research involving mechanically interlocked molecules and molecular machines, and introduces the work of some of the students in his lab, to be discussed at Pittcon 2018.

Other Useful Links

News-Medical.Net provides this medical information service in accordance
with these terms and conditions.
Please note that medical information found
on this website is designed to support, not to replace the relationship
between patient and physician/doctor and the medical advice they may provide.

By continuing to browse or by clicking "Accept All Cookies," you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Find out more.